Bill Text - HB159 (2017)

Adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.


Revision: Jan. 30, 2017, 3:02 p.m.

HB 159 - AS INTRODUCED

 

 

2017 SESSION

17-0116

01/09

 

HOUSE BILL 159

 

AN ACT adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.

 

SPONSORS: Rep. Schleien, Hills. 37; Rep. Fisher, Belk. 9; Rep. Zaricki, Hills. 6; Rep. Josephson, Graf. 11

 

COMMITTEE: Health, Human Services and Elderly Affairs

 

-----------------------------------------------------------------

 

ANALYSIS

 

This bill adds fibromyalgia to the qualifying medical conditions under therapeutic use of cannabis.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

17-0116

01/09

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Seventeen

 

AN ACT adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  Use of Cannabis for Therapeutic Purposes; Definitions.  Amend RSA 126-X:1, IX(a)(1) to read as follows:

(1)  Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C currently receiving antiviral treatment, amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, fibromyalgia, or one or more injuries that significantly interferes with daily activities as documented by the patient's provider; and

2  Effective Date.  This act shall take effect 60 days after its passage.